CV

Cameron Van de Graaf

Principal at Dragoneer

San Francisco Bay Area

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

  • Bachelor's degree with distinction

    (2014 - 2018)

  • Darien High School

    (2010 - 2014)

Work Experience

  • Principal

    2023

  • Investor

    2022 - 2023

    Public / private growth investing

Various

2018

  • Seed Investor / Advisor

    2018

    EZ ICE Rinks (Advisor, previously Interim CFO) Exavir Therapeutics (Investor) Adtech Co. (Investor) Cleantech Co. (Investor) Supply Chain SW Co. (Investor)

2018 - 2021

  • Private Equity Associate

    2020 - 2021

  • Private Equity Analyst

    2018 - 2020

    North America Private Equity - focused on healthcare and technology

2021 - 2021

  • Product Management Extern

    2021 - 2021

    PM extern on newly-launched payroll product

2017 - 2017

  • Associate Consulting Intern

    2017 - 2017

    Private equity group

2017 - 2017

  • Intern

    2017 - 2017

    Developed market landscape for AI startups, contributed to sector thesis, and identified candidate companies. Built out firm’s network of top AI technical talent to support both deal sourcing and portfolio services.

Stanford Consulting

2015 - 2017

  • Project Director

    2015 - 2017

    • Sourced and led a pricing strategy case combining extensive qualitative interviews with a quantitative survey for a rapidly-growing, public financial technology company and presented report to senior client executives • Evaluated the economics of music streaming services and investigated the impact of “unbundling” on various media properties as part of an industry landscape case for a tech-focused boutique investment bank

  • Quantitative Analyst Intern

    2016 - 2016

    Coding & model development at a global macro hedge fund

2015 - 2015

  • Consulting Intern

    2015 - 2015

    Strategy consulting for leading lifestyle and CPG clients

  • Researcher

    2012 - 2014

    Intel Distinguished Research Paper Award for a recombinant protein nanoparticle Lyme disease vaccine